CA
NZ
UK
AU
IND
US
…
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1.21M | -1.93M | -1.63M | - |
| Net income | -0.97M | -1.74M | -1.62M | - |
| Selling general administrative | 0.94M | 1.51M | 0.94M | - |
| Selling and marketing expenses | - | 0.87M | - | - |
| Gross profit | -0.02M | 0.20M | 0.00M | - |
| Reconciled depreciation | 0.01M | 0.00M | 0.00M | - |
| Ebit | -1.12M | -1.93M | -1.63M | -0.38M |
| Ebitda | -1.11M | -1.93M | -1.63M | - |
| Depreciation and amortization | 0.01M | 0.00M | 0.00M | - |
| Operating income | -1.11M | -1.93M | -1.63M | - |
| Other operating expenses | 1.11M | 2.13M | 1.63M | - |
| Interest expense | 0.10M | 0.00M | - | 0.00M |
| Tax provision | -0.24M | -0.19M | -0.02M | - |
| Interest income | 0.00M | 0.00M | - | - |
| Net interest income | -0.10M | 0.00M | - | - |
| Income tax expense | 0.24M | -0.19M | -0.02M | - |
| Total revenue | 0.00M | 0.20M | 0.00M | - |
| Total operating expenses | 1.10M | 2.13M | 1.63M | - |
| Cost of revenue | 0.02M | 0.00M | 0.00M | - |
| Total other income expense net | -0.10M | 0.00M | - | - |
| Net income from continuing ops | -0.97M | -1.74M | -1.62M | - |
| Net income applicable to common shares | - | - | -1.62M | -0.69M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5.75M | 6.09M | 7.77M | 4.56M |
| Intangible assets | 5.06M | 5.06M | 5.06M | 1.20M |
| Other current assets | - | 0.16M | - | - |
| Total liab | 0.86M | 0.59M | 0.56M | 0.48M |
| Total stockholder equity | 4.89M | 5.50M | 7.21M | 4.08M |
| Other current liab | 0.16M | 0.16M | 0.21M | 0.15M |
| Common stock | 1.36M | 1.29M | 1.29M | 0.72M |
| Capital stock | 1.36M | 1.29M | 1.29M | 0.72M |
| Retained earnings | -5.27M | -4.29M | -2.55M | -0.91M |
| Other liab | - | - | 0.28M | 0.28M |
| Good will | 0.28M | 0.28M | 0.28M | 0.28M |
| Cash | 0.34M | 0.54M | 2.32M | 0.90M |
| Total current liabilities | 0.58M | 0.31M | 0.28M | 0.20M |
| Net debt | 0.06M | -0.54M | -2.32M | -0.90M |
| Short term debt | 0.40M | - | - | - |
| Short long term debt | 0.40M | 0.00M | - | - |
| Short long term debt total | 0.40M | - | - | - |
| Other stockholder equity | 4.62M | 4.40M | 8.46M | 4.28M |
| Total current assets | 0.36M | 0.69M | 2.42M | 3.08M |
| Net tangible assets | - | - | 1.86M | 2.60M |
| Net receivables | 0.03M | 0.16M | 0.10M | 2.15M |
| Inventory | - | -0.16M | - | - |
| Accounts payable | 0.02M | 0.14M | 0.07M | 0.04M |
| Accumulated other comprehensive income | 4.18M | 4.10M | - | - |
| Non currrent assets other | - | 5.06M | - | - |
| Non current assets total | 5.39M | 5.39M | 5.34M | 1.48M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -0.05M | -0.10M | - |
| Change to liabilities | - | - | 0.06M | 0.10M |
| Total cashflows from investing activities | - | -0.05M | -0.10M | -0.83M |
| Net borrowings | 0.58M | 0.00M | - | - |
| Total cash from financing activities | 0.58M | -0.00M | 3.10M | 3.47M |
| Net income | -1.21M | -1.74M | -1.63M | -0.69M |
| Change in cash | -0.20M | -1.79M | 1.42M | 0.67M |
| Begin period cash flow | 0.54M | 2.32M | 0.90M | - |
| End period cash flow | 0.34M | 0.54M | 2.32M | 0.90M |
| Total cash from operating activities | -0.78M | -1.73M | -1.58M | -1.97M |
| Issuance of capital stock | - | - | 3.12M | - |
| Depreciation | 0.01M | 0.00M | 0.00M | - |
| Other cashflows from investing activities | - | 0.00M | - | - |
| Change to inventory | - | - | 0.00M | 0.01M |
| Change to account receivables | 0.13M | -0.06M | -0.02M | -1.60M |
| Other cashflows from financing activities | - | -0.00M | -0.02M | -0.12M |
| Change to netincome | - | - | -0.00M | 0.21M |
| Capital expenditures | 0.00M | 0.05M | 0.00M | 0.00M |
| Change in working capital | 0.01M | -0.03M | 0.04M | - |
| Stock based compensation | 0.02M | 0.01M | 0.01M | - |
| Other non cash items | 0.39M | 0.03M | 0.01M | - |
| Free cash flow | -0.78M | -1.79M | -1.58M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GNS Genus PLC |
18.00 0.78% |
2340.00 | 36.08 | 26.18 | 2.53 | 3.46 | 2.92 | 15.38 |
| ONT Oxford Nanopore Technologies Ltd |
10.60 4.93% |
225.60 | - | - | 4.71 | 2.50 | 4.23 | -8.89 |
| OXB Oxford BioMedica PLC |
5.00 0.95% |
532.00 | - | 208.33 | 4.05 | 7.60 | 4.42 | 308.96 |
| AVCT Avacta Group PLC |
-1.00 1.60% |
61.50 | - | - | 2849.46 | 1929.84 | 2525.51 | -12.04 |
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
85 Great Portland Street, London, United Kingdom, W1W 7LT
44 20 3918 8633
7
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen Paul West B.Com, CA | Exec. Chairman | 1973 |
| Mr. Trevor Ajanthan Reginald | CEO & Exec. Director | NA |
| Prof. Martin J. Evans FRS | Group Chief Scientific Officer & Exec. Director | NA |
| Dr. Armand Keating M.D. | Independent Chief Medical Officer | NA |
| Mr. Stephen Paul West B.Com, CA | Executive Chairman | 1972 |
| Dr. Darrin Matthew Disley O.B.E., Ph.D. | Interim MD & Director | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...